Compass Therapeutics, Inc.
CMPXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Compass Therapeutics, Inc. focuses on Biotechnology services and products. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. With a market capitalization of $374.6M, it sits in small-cap territory. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Market Cap
$374.6M
Beta
0.67
P/E (TTM)
—
P/E (Fwd)
-4.52
EPS (TTM)
$-0.40
EPS (Fwd)
$-0.46
ROE
-46.0%
ROA
-27.9%
Cash
$194.7M
Total Debt
$9.8M
Free CF
-$30.0M
52W Change
-4.2%
Annual Financials
Cash vs Debt
With $194.7M in cash and $9.8M in debt, CMPX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$30.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -46.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.67 suggests CMPX is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Compass Therapeutics, Inc. and its sector.